Biogaia Ab Class B · OMXSTO:BIOG_B
Biogaia Ab Class B — Q1 2025 Earnings Presentation
16 slides from Biogaia Ab Class B's earnings presentation, May 7, 2025
Slide 1: Q1 2025 Results
Q1 2025 RESULTS Telephone Conference 7 May 2025 Theresa Agnew, CEO Alexander Kotsinas, CFO
Slide 2: Executive Summary Q1 2025
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Executive Summary Q1 2025 • Sales were 366 MSEK (-1%) due to lower sales in APAC and EMEA • Sales in EMEA decreased by 23%, in APAC by 19%, while Americas increased by 42%
Slide 3: Launches
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Launches Distributor Country Product Medicatrix Morocco BioGaia Protectis drops Medicatrix Morocco BioGaia Protectis tablets Abbott Nicaragua BioGaia Protectis drops Abbott
Slide 4: Key Events
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Key Events • January 16: BioGaia announced that in line with its long-term successful strategy to market and sell its products through its own subsidiaries in certain prior
Slide 5: Sales per Segment
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Sales per Segment Sales per Segment Q1 2025 0% MSEK Q1 2025 Q1 2024 Change 26% Pediatrics 270 292 -8% Adult Health 95 75 26% Other 2 3 -34% 74% Total 366 370 -1% Pediatrics
Slide 6: Sales per Region
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Sales per Region Sales per Region Q1 2025 MSEK Q1 2025 Q1 2024 Change EMEA 124 162 -23% 47% 34% APAC 69 86 -19% Americas 174 123 42% Total 366 370 -1% 19% EMEA • EMEA: sale
Slide 7: Financials
Alexander Kotsinas, CFO Financials 7
Slide 8: Key Financials
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Key Financials Sales (MSEK) Gross profit (MSEK) EBIT (MSEK) +1% -1% 266 268 -32% 370 366 143 97 72% 73% 39% 27% Q1 2024 Q1 2025 Q1 2024 Q1 2025 Q1 2024 Q1 2025 8
Slide 9: Sales Bridge
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Sales Bridge -1% 370 366 -13 10 Q1 2024 Organic Currency Q1 2025 growth effect Change -4% +3% 9
Slide 10: Gross Margin per Segment
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Gross Margin per Segment Gross margin Q1 2025 Q1 2024 Pediatrics 75% 75% Adult Health 67% 57% Total 73% 72% • Adult Health: gross margin increased due to a more favorable g
Slide 11: Operating Expenses (OPEX)
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Operating Expenses (OPEX) MSEK Q1 2025 Q1 2024 Change Sales and Marketing -113 -96 18% Research and Development -23 -25 -10% Administration -11 -14 -20% Other OPEX -24 12 -
Slide 12: Profit and Loss Statement
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Profit and Loss Statement MSEK Q1 2025 Q1 2024 Change Sales 366 370 -1% Gross profit 268 266 1% Percentage of revenue 73% 72% OPEX -171 -123 40% EBIT 97 143 -32% Percentage
Slide 13: Cashflow
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Cashflow MSEK Q1 2025 Q1 2024 Change Cash flow from operating activities before changes 81 123 -34% in net working capital Changes in working capital -45 -71 -36% Cash flow
Slide 14: Concluding Remarks
Executive summary Executive summary Sales breakdown Sales breakdown Financials Financials Concluding remarks remarks Concluding Concluding Remarks Q1 2025 • Following a year of strong growth and continued global expansion, BioGaia enters 2025 with sales relatively flat versus last year, anticipating
Slide 15: Q&A
Q&A
Slide 16: BioGaia.
BioGaia.